Variation in general practice prostate-specific antigen testing and prostate cancer outcomes: An ecological study

International Journal of Cancer

Volumn 136, Issue 2, 2015, Pages 435-442

  Hjertholm, Peter ^a   Fenger Grøn, Morten ^a   Vestergaard, Mogens ^a   Christensen, Morten B ^a   Borre, Michael ^b   Møller, Henrik ^a,c   Vedsted, Peter ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c GUY S HOSPITAL   (United Kingdom)

Author keywords

general practice; neoplasm; primary health care; prostate neoplasms; prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; DIAGNOSTIC TEST; GENERAL PRACTICE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RISK FACTOR; TRANSRECTAL ULTRASONOGRAPHY; TUMOR BIOPSY; VERY ELDERLY; BLOOD; CLINICAL PRACTICE; COHORT ANALYSIS; DENMARK; EARLY DIAGNOSIS; ECOLOGY; EPIDEMIOLOGY; FOLLOW UP; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PROGNOSIS; PROSTATIC NEOPLASMS; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; TRENDS;

AGED; COHORT STUDIES; COMBINED MODALITY THERAPY; DENMARK; EARLY DETECTION OF CANCER; ECOLOGY; FOLLOW-UP STUDIES; GENERAL PRACTICE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PHYSICIAN'S PRACTICE PATTERNS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 84922323173     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29008     Document Type: Article

References (31)

1. Baade PD, Youlden DR, Krnjacki LJ,. International epidemiology of prostate cancer: geographical distribution and secular trends. Mol Nutr Food Res 2009; 53: 171-84.
2. Bray F, Klint Å, Gislum M, et al., Trends in survival of patients diagnosed with male genital cancers in the Nordic countries 1964-2003 followed up until the end of 2006. Acta Oncol 2010; 49: 644-54.
3. Pedersen KM, Andersen JS, Søndergaard J,. General Practice and Primary Health Care in Denmark. J Am Board Fam Med 2012; 25: S34-8.
4. DACROPA. Available at: http://ducg.dk/prostata/retningslinjer. Accessed September 5, 2013.
5. Pedersen CB,. The Danish Civil Registration System. Scand J Public Health 2011; 39: 22-5.
6. Grann AF, Erichsen R, Nielsen AG, et al., Existing data sources for clinical epidemiology: The clinical laboratory information system (LABKA) research database at Aarhus University, Denmark. Clin Epidemiol 2011; 3: 133-8.
7. Lynge E, Sandegaard JL, Rebolj M,. The Danish National Patient Register. Scand J Public Health 2011; 39: 30-3.
8. International Classification of Diseases. Available at: http://www.who.int/classifications/icd/en/. Accessed January 28, 2013.
9. Gjerstorff ML,. The Danish Cancer Registry. Scand J Public Health 2011; 39: 42-5.
10. Nguyen-Nielsen M, Froslev T, Friis S, et al., Completeness of prostate cancer staging in the Danish Cancer Registry, 2004-2009. Clin Epidemiol 2012; 4 (Suppl 2): 17-23.
11. Helweg-Larsen K,. The Danish register of causes of death. Scand J Public Health 2011; 39: 26-9.
12. Sundararajan V, Quan H, Halfon P, et al., International Methodology Consortium for Coded Health Information (IMECCHI). Cross-national comparative performance of three versions of the ICD-10 Charlson index. Med Care 2007; 45: 1210-15.
13. Thygesen S, Christiansen C, Christensen S, et al., The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients. BMC Med Res Methodol 2011; 11: 83.
14. Williams RL,. A note on robust variance estimation for cluster-correlated data. Biometrics 2000; 56: 645-6.
15. Corazziari I, Quinn M, Capocaccia R,. Standard cancer patient population for age standardising survival ratios. Eur J Cancer 2004; 40: 2307-16.
16. Dickman PW, Sloggett A, Hills M, et al., Regression models for relative survival. Stat Med 2004; 23: 51-64.
17. Franks P, Mooney C, Sorbero M,. Physician referral rates: style without much substance? Med Care 2000; 38: 836-46.
18. O'Kane MJ, Casey L, Lynch PLM, et al., Clinical outcome indicators, disease prevalence and test request variability in primary care. Ann Clin Biochem 2011; 48: 155-8.
19. Hippisley-Cox J, Hardy C, Pringle M, et al., Are patients who present late with cancer registered with low referring practices? Br J Gen Pract 1997; 47: 731-2.
20. Shawihdi M, Thompson E, Kapoor N, et al., Variation in gastroscopy rate in English general practice and outcome for oesophagogastric cancer: retrospective analysis of Hospital Episode Statistics. Gut 2014; 63: 250-61.
21. Lu-Yao G, Albertsen PC, Stanford JL, et al., Screening, treatment, and prostate cancer mortality in the Seattle area and Connecticut: fifteen-year follow-up. J Gen Intern Med 2008; 23: 1809-14.
22. Shao YH, Albertsen PC, Shih W, et al., The impact of PSA testing frequency on prostate cancer incidence and treatment in older men. Prostate Cancer Prostatic Dis 2011; 14: 332-9.
23. Schroder FH, Hugosson J, Roobol MJ, et al., Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012; 366: 981-90.
24. Outzen M, Brasso K, Martinussen N, et al., Prostate cancer in Denmark 1978-2009-trends in incidence and mortality. Acta Oncol 2013; 52: 831-6.
25. Welch HG, Albertsen PC,. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Instit 2009; 101: 1325-9.
26. Sandblom G, Varenhorst E, Löfman O, et al., Clinical consequences of screening for prostate cancer: 15 years follow-up of a randomised controlled trial in Sweden. Eur Urol 2004; 46: 717-24.
27. Brasso K, Ingimarsdottir IJ, Rusch E, et al., Differences in survival from prostate cancer in Denmark, Iceland and Sweden. Eur J Cancer 2013; 49: 1984-92.
28. Wilt TJ, Brawer MK, Jones KM, et al., Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012; 367: 203-13.
29. Finne P, Fallah M, Hakama M, et al., Lead-time in the European randomised study of screening for prostate cancer. Eur J Cancer 2010; 46: 3102-8.
30. Ilic D, Neuberger MM, Djulbegovic M, et al., Screening for prostate cancer. Cochrane Database Syst Rev 2013; 1: CD004720.
31. Borre M,. Screening by lower urinary tract symptoms vs asymptomatic prostate-specific antigen levels leading to radical prostatectomy in Danish men: tumour characteristics and treatment outcome. BJU Int 2009; 104: 205-8.